Masitinib

Generic Name: Masitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₀N_₆OS

CAS Number: 790299-79-5

Unique Ingredient Identifier: M59NC4E26P

Background: Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Phase 2

Completed

Conditions: Gastro Intestinal Stromal Tumor

Interventions: Drug: masitinib
Drug: sunitinib

First Posted Date: 2012-01-10

Last Posted Date: 2018-12-11

Lead Sponsor: AB Science

Target Recruit Count: 44

Registration Number: NCT01506336

Locations: 🇫🇷
Institute Gustave Roussy (IGR), Villejuif, France

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Placebo
Drug: Masitinib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2011-11-11

Last Posted Date: 2018-12-19

Lead Sponsor: AB Science

Target Recruit Count: 147

Registration Number: NCT01470131

Locations: 🇺🇸
Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States
🇫🇷
CHU Estaing, Clermont Ferrand, France
🇫🇷
CH Le Mans, Le Mans, France

and more 10 locations

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: masitinib

First Posted Date: 2011-10-12

Last Posted Date: 2018-12-11

Lead Sponsor: AB Science

Target Recruit Count: 35

Registration Number: NCT01450488

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Masitinib

First Posted Date: 2011-10-10

Last Posted Date: 2021-02-10

Lead Sponsor: AB Science

Target Recruit Count: 420

Registration Number: NCT01449162

Locations: 🇫🇷
Hospital La Cavale Blanche, Brest, France
🇨🇿
Hospital Polyclinic Melnik, Mělník, Czechia
🇫🇷
l'Hopital Albert Calmette, Lille, France

and more 5 locations

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Relapse Free

Interventions: Drug: Masitinib
Drug: Placebo

First Posted Date: 2011-09-14

Last Posted Date: 2020-04-08

Lead Sponsor: AB Science

Target Recruit Count: 656

Registration Number: NCT01433497

Locations: 🇫🇷
Hôpital de Gui de Chauliac, Montpellier, France
🇧🇬
"St. Ivan Rilski" University Multiprofile Hospital for Active Treatment, Sofia, Bulgaria
🇫🇷
GHICL hopital ST vincent de Paul, Lille, France

and more 5 locations

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Phase 3

Terminated

Conditions: Metastatic Melanoma

Interventions: Drug: Dacarbazine
Drug: Masitinib

First Posted Date: 2011-01-21

Last Posted Date: 2020-11-05

Lead Sponsor: AB Science

Target Recruit Count: 134

Registration Number: NCT01280565

Locations: 🇺🇸
Blumenthal Cancer Centre, Charlotte, North Carolina, United States
🇫🇷
Centre Hospitalier LE MANS, Le Mans, France
🇨🇿
University Hospital Hradec Králové, Hradec Králové, Czechia

and more 6 locations

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

Phase 2

Completed

Conditions: Mastocytosis

Interventions: Drug: masitinib

First Posted Date: 2010-12-24

Last Posted Date: 2018-12-10

Lead Sponsor: AB Science

Target Recruit Count: 21

Registration Number: NCT01266369

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Placebo
Drug: Masitinib

First Posted Date: 2010-01-11

Last Posted Date: 2018-12-10

Lead Sponsor: AB Science

Target Recruit Count: 25

Registration Number: NCT01045577

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: masitinib

First Posted Date: 2009-06-04

Last Posted Date: 2018-12-13

Lead Sponsor: AB Science

Target Recruit Count: 20

Registration Number: NCT00913432

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

Phase 3

Completed

Conditions: Indolent Systemic Mastocytosis

Interventions: Drug: Placebo
Drug: Masitinib
Other: Best Supportive Care

First Posted Date: 2008-12-23

Last Posted Date: 2019-12-03

Lead Sponsor: AB Science

Target Recruit Count: 135

Registration Number: NCT00814073

Locations: 🇺🇸
UC Davis Health System , Department of Dermatology, Sacramento, California, United States
🇺🇸
MD Anderson Cancer Centre, Houston, Texas, United States
🇫🇷
Hôpital Nord, Marseille, France

and more 21 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy